Recombinant Human NRAS(mutated Q61R) Protein (His tag) is a Human Full Length protein, expressed in Escherichia coli, with >=95% purity, = 0.005 EU/µg endotoxin level and suitable for MS.
>=95% HPLC
= 0.005 EU/µg
Escherichia coli
His tag N-Terminus
MS
No
LC-MS/MS
T E Y K L V V V G A G G V G K S A L T I Q L I Q N H F V D E Y D P T I E D S Y R K Q V V I D G E T C L L D I L D T A G R E E Y S A M R D Q Y M R T G E G F L C V F A I N N S K S F A D I N L Y R E Q I K R V K D S D D V P M V L V G N K C D L P T R T V D T K Q A H E L A K S Y G I P F I E T S A K T R Q G V E D A F Y T L V R E I R Q Y R M K K L N S S D D G T Q G C M G L P C
Application | Reactivity | Dilution info | Notes |
---|---|---|---|
Application MS | Reactivity Reacts | Dilution info - | Notes - |
Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.
GTPase NRas, Transforming protein N-Ras, HRAS1, NRAS
Recombinant Human NRAS(mutated Q61R) Protein (His tag) is a Human Full Length protein, expressed in Escherichia coli, with >=95% purity, = 0.005 EU/µg endotoxin level and suitable for MS.
GTPase NRas, Transforming protein N-Ras, HRAS1, NRAS
>=95% HPLC
= 0.005 EU/µg
Escherichia coli
His tag N-Terminus
MS
No
LC-MS/MS
Yes
Human
pH: 7
Constituents: 20% Glycerol (glycerin, glycerine), 0.2691% Sodium phosphate dibasic heptahydrate, 0.1629% Sodium Phosphate Monobasic, 0.0148% (R*,R*)-1,4-Dimercaptobutan-2,3-diol
T E Y K L V V V G A G G V G K S A L T I Q L I Q N H F V D E Y D P T I E D S Y R K Q V V I D G E T C L L D I L D T A G R E E Y S A M R D Q Y M R T G E G F L C V F A I N N S K S F A D I N L Y R E Q I K R V K D S D D V P M V L V G N K C D L P T R T V D T K Q A H E L A K S Y G I P F I E T S A K T R Q G V E D A F Y T L V R E I R Q Y R M K K L N S S D D G T Q G C M G L P C
Full Length
22.26 kDa
22.12 kDa
Recombinant
His tag N-Terminus
Liquid
Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.
Belongs to the small GTPase superfamily. Ras family.
Palmitoylated by the ZDHHC9-GOLGA7 complex (PubMed:16000296). Depalmitoylated by ABHD17A, ABHD17B and ABHD17C (PubMed:26701913). A continuous cycle of de- and re-palmitoylation regulates rapid exchange between plasma membrane and Golgi (PubMed:16000296, PubMed:15705808, PubMed:2661017, PubMed:26701913).
Dry Ice
-80°C
-80°C
The NRAS protein also known as neuroblastoma RAS viral oncogene homolog has a molecular weight of approximately 24 kDa. It functions mechanically as a GTPase cycling between an inactive GDP-bound state and an active GTP-bound state. The NRAS gene which encodes this protein shows expression in various tissues including the thymus leukocytes and other cells of the hematopoietic lineage. Activation of RAS involves the conversion to the GTP-bound form which enables NRAS to transmit signals within cells.
NRAS plays an important role in cell proliferation differentiation and survival. It does not function alone but is part of the larger RAS protein family including HRAS and KRAS with whom it shares similar roles and sequence homology. NRAS interacts with various growth factor receptors and mediates signals to downstream effectors that influence cellular processes. Mutations in the NRAS gene can affect these biological processes leading to altered cell behavior.
NRAS has significant roles in the MAPK/ERK pathway and the PI3K/AKT pathway. These pathways regulate fundamental cellular functions including growth and survival. NRAS interacts closely with other proteins such as RAF kinases and PI3K to propagate signals from activated receptors at the cell membrane to the nucleus. Altered NRAS activity can impact these pathways affecting cellular responses to external stimuli.
NRAS mutations are linked to certain cancers including melanoma and acute myeloid leukemia (AML). Mutant forms of NRAS result in constitutively activated RAS contributing to uncontrolled cell growth and survival. In melanoma NRAS mutations frequently co-occur with alterations in other proteins such as BRAF another member of the RAS/RAF/MEK/ERK pathway. Understanding NRAS's involvement in these conditions is critical for developing targeted therapeutic strategies.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Mass determination by ESI-TOF.
Predicted MW is 22260 Da (+/- 10 Da by ESI-TOF). Observed MW is 22124.78 Da.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com